Retatrutide is an investigational triple agonist peptide that targets three key metabolic receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor
Keep swirling gently it will dissolve completely with patience
Trials that establish the optimal dosing of GLP-1 RAs for effective weight loss in patients with breast cancer, particularly those on endocrine therapies, are requisite for probing the potential anticancer impact
These may affect a smaller group of patients: Although rare, some patients may experience: GLP-1 receptor agonists are contraindicated in individuals with: Its important to share your complete medical history with your doctor before starting treatmentespecially if you have existing gastrointestinal, gallbladder, or thyroid concerns
This contrasts sharply with brand-name GLP-1 options, where dose escalation often triggers price jumps of $50$150 per refill